Biodesix, a Boulder, CO-based molecular diagnostics company, has been busy on the financing front, announcing today it has raised an additional $6.1 million from investors in an equity sale. The company also secured a $20 million debt facility last week. Biodesix is developing VeriStrat, a test that can be used during the treatment of advanced non-small cell lung cancer.
Help employers find you! Check out all the jobs and post your resume.
